|
Latest Advances in Person-Centric HIV Treatment Research and the Impact of Global Collaboration
October 16, 2023 — Gilead announced plans to present new long-term and real-world HIV treatment research data at the 19th European AIDS Conference (EACS) taking place October 18-21 in Warsaw, Poland and virtually, as part of the company’s leading efforts to drive person-centric advances in HIV through scientific research and its focus on forging community partnership to help end the HIV epidemic.
As a leader in scientific innovation in HIV, Gilead will present research that will offer insights into how treatment with Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) and Sunlenca® (lenacapavir 463.5 mg/1.5 mL injection) may help inform the future of coordinated, person-centered HIV Care. Specifically:
- Three-year efficacy, safety and tolerability data evaluating Biktarvy from the ongoing global, observational, real-world BICSTaR study in a diverse range of treatment-naïve and treatment-experienced people with HIV who have a high burden of co-morbidities.
- New findings on long-acting HIV treatment strategies, including outcomes from multiple studies evaluating twice-yearly Sunlenca, Gilead’s first-in-class, long-acting HIV-1 capsid inhibitor. These findings will include insights, experience and perspectives from healthcare professionals and study coordinators from CAPELLA. Additional lenacapavir data presented at EACS 2023 will provide insight into the therapy’s resistance profile.
In addition, Gilead will share updates on innovative collaborations, including initiatives aimed at helping advance efforts to end the HIV epidemic in Eastern Europe and Central Asia, and convene two symposia profiling the current HIV journey, treatment landscape, real-world implementation, and best practice learnings for healthcare providers to examine the barriers and challenges in helping people with HIV reach and sustain long-term success.
Please advise if you are interested in an interview with Jared Baeten, VP, HIV Clinical Development at Gilead Sciences and/or a study investigator to discuss the above data being presented at EACS 2023.
Please click here to view the full Prescribing Information for Biktarvy, including Boxed Warning.
Please click here to view the full Prescribing Information for Sunlenca.
Contact:
Brian Plummer,
Senior Director, Global Public Affairs – HIV
Cell: (202) 309-5207
Email:brian.plummer@gilead.com
Source: Gilead Sciences, Inc.
"Reproduced with permission - GILEAD"
GILEAD
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
